Active clinical trials for Dermatology:

TITLE DESCRIPTION
A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis The primary objective of the study is to evaluate the dose response of bimekizumab (also known as UCB4940) administered subcutaneously (sc) every 4 weeks (Q4W) for 12 weeks in the treatment of subjects with moderate to severe chronic plaque psoriasis.
More information
A phase 3 clinical trial to evaluate the efficacy and safety of a topical investigational medication (LEO 43204 gel 0.037%) for the treatment of Actinic Keratosis (sun spots) on balding scalp. To determine the safety and effectiveness of LEO 43204 gel on sun spots of the balding scalp
More information
A Phase 3 Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate to Severe Atopic Dermatitis This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with maderate to severe AD (Atopic Dermatitis).The study is either 16 weeks (16 week treatment period) or 28 weeks (16-week treatment period and 12-week follow up), depending on whether or not patients continue in a maintenece or extension study.
More information
Photodynamic Therapy for Papulopustular Rosacea Dermatology at The GW Medical Faculty Associates is conducting an experimental research study to examine the efficacy of 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) in treating rosacea. The purpose of this study is to evaluate if using 5-ALA PDT improves rosacea symptoms. We are seeking individuals with rosacea between the ages of 18 and 79 to volunteer to participate in this study. This study will take a total of six months (six total visits to the MFA). Prior to each visit, you will be examined and fill out a questionnaire. Participation in the study will be of no direct cost to you. If you are interested in participating in this research study, please contact Dermatology at The GW Medical Faculty Associates.
More information
Study for patients with moderate to severe Chronic Plaque Psoriasis - A Phase 3, Randomized, double-blind and open label study to test the safety and efficacy of Certolizumab Pegol in subjects with moderate to severe Chronic Plaque Psoriasis The study will test the safety and effectiveness of Certolizumab Pegol vs placebo in patients with Chronic Plaque Psoriasis. An Open Label study will follow the placebo phase.
More information